04/23/2014 | US/Eastern ENP Newswire .
Barcelona, : Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), a leader in the production of plasma-derived medicines, achieved the 'Highly Protected Risk' (HPR) certification at its Los Angeles site, the highest recognition an industrial site may obtain in terms of prevention and protection.
The process to achieve the award, implemented by FM Global, a property damage insurance company, consists in assessing and engineering the risk, helping to prevent it, in mitigating losses.
The certification recognizes the following criteria are met at the Los Angeles plasma protein production site:
.Knows its risk and maintains a risk reduction process.
.Has established all needed human element programs to reduce frequency of losses. A HPR site has four times less probability to have a loss compared to non-HPR sites.
.Has implemented all reasonable protection measures to reduce the gravity of a loss, including losses caused by natural hazards. Compared to non-HPR sites, the average gross loss on a HPR site is 10 times less. to avoid large losses to occur
.The business interruption potential of the site in case of loss is minimized.
The HPR award to the Los Angeles site is in line with the Grifols' commitment to guarantee plasma protein production and prevent potential production capacity losses. The award is the result of Grifols constant efforts to maintain its position as trusted supplier to patients and healthcare professionals.
(c) 2014 Electronic News Publishing -